The risk of hypoglycemia with tirzepatide remains low, consistent with other GLP-1 receptor agonists, particularly in the absence of concomitant Insulin or sulfonylureas (Frias et al. 2021). This evidence concerns the gene GLP1R and Hypoglycemia.